biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by BearDownAZon Jul 21, 2015 11:03pm

161 Views

Post# 23947207

RE:RE:News: Bioasis, Harvard teaching hospital to work with Transc

This is great news! It goes without saying that Harvard and Brigham and Women's Hospital are top notch institutions. This research and collaboration agreement will be great exposure for BiOasis in the US and beyond. In addition to the respect garnered from collaborations with Scarpa on the LSD front, this will bring even more respect to the neuro-oncology applications and to the MTfp carrier in general. But it is also very intriguing that this Harvard/BWH research collaboation will further explore MTfp-siRNA and MTfp-miRNA in neuro-oncology applications. I look forward to hearing much more about this. Recently, in a BioTuesdays article, BiOasis revealed that they plan to file an IND in 2016 for Mtfp-TZM (Trastuzumab). From this latest BiOasis press release now it sounds like Harvard/BWH will be intimately involved in this human clinical trial. As stated in the press release, "The work will include moving the trastuzumab program forward towards human clinical trials." Great news today. Hopefully more dominos continue to fall in the near future.

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale